VSTM vs KPTI vs PTCT vs FOLD vs IQV vs JPM

For growth investors, Verastem, Inc.

(VSTM) is the stronger pick with 209. 1% revenue growth year-over-year, versus 0. 6% for Karyopharm Therapeutics Inc. (KPTI). PTC Therapeutics, Inc. (PTCT) offers the better valuation at 9. 7x trailing P/E (84. 8x forward), making it the more compelling value choice. Analysts rate Verastem, Inc. (VSTM) a "Buy" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, PTC Therapeutics, Inc.

(PTCT) is the cheapest at 9. 7x versus IQVIA Holdings Inc. at 23. 1x. On forward P/E, IQVIA Holdings Inc. is actually cheaper at 14. 2x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: IQVIA Holdings Inc. wins at 0. 35x versus JPMorgan Chase & Co. 's 0. 81x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, JPMorgan Chase & Co.

(JPM) delivered a total return of +118. 2%, compared to -93. 9% for Karyopharm Therapeutics Inc. (KPTI). Over 10 years, the gap is even starker: PTCT returned +995. 3% versus KPTI's -92. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Amicus Therapeutics, Inc.

(FOLD) is the lower-risk stock at 0. 48β versus Verastem, Inc. 's 1. 64β — meaning VSTM is approximately 239% more volatile than FOLD relative to the S&P 500. On balance sheet safety, Verastem, Inc. (VSTM) carries a lower debt/equity ratio of 134% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Verastem, Inc.

(VSTM) is pulling ahead at 209. 1% versus 0. 6% for Karyopharm Therapeutics Inc. (KPTI). On earnings-per-share growth, the picture is similar: PTC Therapeutics, Inc. grew EPS 264. 5% year-over-year, compared to -90. 5% for Karyopharm Therapeutics Inc.. Over a 3-year CAGR, VSTM leads at 128. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

PTC Therapeutics, Inc.

(PTCT) is the more profitable company, earning 39. 4% net margin versus -677. 6% for Verastem, Inc. — meaning it keeps 39. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PTCT leads at 49. 5% versus -550. 3% for VSTM. At the gross margin level — before operating expenses — KPTI leads at 95. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, IQVIA Holdings Inc. (IQV) is the more undervalued stock at a PEG of 0. 35x versus JPMorgan Chase & Co. 's 0. 81x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, IQVIA Holdings Inc. (IQV) trades at 14. 2x forward P/E versus 84. 8x for PTC Therapeutics, Inc. — 70. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for VSTM: 345. 1% to $18. 25.

In this comparison, JPM (1.

9% yield) pays a dividend. VSTM, KPTI, PTCT, FOLD, IQV do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, JPMorgan Chase & Co.

(JPM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 94), 1. 9% yield, +465. 8% 10Y return). Verastem, Inc. (VSTM) carries a higher beta of 1. 64 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (JPM: +465. 8%, VSTM: -75. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (VSTM (Healthcare) and KPTI (Healthcare) and PTCT (Healthcare) and FOLD (Healthcare) and IQV (Healthcare) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: VSTM is a small-cap high-growth stock; KPTI is a small-cap quality compounder stock; PTCT is a small-cap high-growth stock; FOLD is a small-cap high-growth stock; IQV is a mid-cap quality compounder stock; JPM is a large-cap deep-value stock. JPM pays a dividend while VSTM, KPTI, PTCT, FOLD, IQV do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.